Summary

Triple disease-modifying antirheumatic drug (DMARD) therapy is superior to methotrexate monotherapy on measures of disease activity as initial treatment for rheumatoid arthritis (RA). The design and results of the multicenter stratified single-blind Treatment in the Rotterdam Early Arthritis Cohort trial [tREACH] comparing treatment strategies, including different glucocorticoid bridging therapies, in adults with early RA are discussed in this article